were recorded.
Results: Of the total 856 renal transplant recipients, a total of 93 (10.8%) patients were found to have some clinical, laboratory, or radiological evidence of neurological involvement. A total of 69 (73.3%) developed CNS complications with a mortality rate of 37.7%. CNS infections occurred in 47 (5% of total) recipients and accounted for the largest group (68.1%). Fungi were the commonest etiological agents, 22 (46.8%), and were associated with 40% mortality. Cryptococcal meningitis was occurring in 19 (27.5%), with mortality in 31.6% of these. Other fungal infections were aspergillosis in two and mucormycosis in one. All patients with aspergillosis and mucormycosis had a fatal outcome. The second largest group on CNS complications comprised of patients with cerebrovascular accidents, which occurred in 13 patients (18.8%), and were associated with a mortality of 23%. Eight patients with ischemic stroke had survived. Two had hemorrhagic stroke and both had a fatal outcome.
Three patients had subdural hematoma with 33.3% mortality. Four patients had toxic encephalopathy as a result of fulminant systemic sepsis with mortality in all. Other less common CNS complications included intracranial space occupying lesion in two, postoperative psychosis in two, and hypoglycemic coma in one. There was no relationship between the development of infection or stroke and the type of maintenance immunosuppression 1.
Introduction
The kidney is the most frequently transplanted organ with more than 10,000 transplants occurring per year worldwide. Since the landmark operation by Murray in Boston in 1954 in which an identical twin received a donated sibling kidney, kidney transplants have developed into the best-accepted therapy for most causes of end-stage renal failure. 1 The 1year survival rate is close to 100%, with an 85-95% graft survival rate. 2 However, despite these advances, neurologic complications after renal transplants occur in a significant percentage of patients. An early, large retrospective study found neurological complication to be 30% over an 18-year period. 7 Two more recent studies have found lower rates, 8% and 10% over a 26-year period and 19-year period, respectively. 5, 6 Several characteristics of renal transplant patients make overall complication rates in these persons different from those of other organ transplant recipients. Many renal transplant patients have some degree of vascular compromise either as a result of their underlying disease (e.g., hypertension, diabetes) or because of emboli associated with underlying atherosclerosis or heart disease. 8 After transplant, neurologic complications may develop secondary to the transplant itself, the immunosuppressive agent, or a previously known organ parenchymal failure. The most common neurological complications seen with renal transplantation are neurotoxicity attributable to immunosuppressive drugs, opportunistic central nervous system (CNS) infections, cerebrovascular events, encephalopathy, and de novo CNS neoplasms. Amongst immunosuppressants, calcineurin inhibitors are the main drugs involved in neurotoxicity, leading to complications, which range from mild symptoms, such as tremors and paresthesias, to severe symptoms, such as disabling pain syndrome and leukoencephalopathy. Indeed in some reports, opportunistic infections of the CNS are second in frequency to those of the lung as a cause of morbidity and mortality. 9 Neurological complications can be broadly divided into those involving the CNS and the peripheral nervous system (PNS). CNS dysfunction localizes to any abnormality of brain and spinal cord. PNS dysfunction localizes to nerve roots (radiculopathy), peripheral nerves (neuropathy), and muscle (myopathy). Since there are not many reports on this subject and because epidemiology of various infective agents varies according to geographical locations, we present our experience on various neurological complications encountered in renal transplant patients in our institute over a period of 8 years, from 2002 to 2009.
2.
Patients and methods Occurrence of acute rejections, biopsy proven chronic allograft nephropathy (CAN), delayed graft function (DGF), and new onset diabetes after transplant (NODAT) were recorded. All acute rejections were confirmed by graft biopsy, and delayed graft function (DGF) was defined as need of dialysis within 1 week after transplantation; new onset diabetes (NODAT) was defined as per the American Diabetes Association criteria. The use of immunosuppressive drugs with doses and induction with anti-thymocyte globulin (ATG) and IL-2Ra blockers were recorded.
Neurological complications were broadly categorized into complications involving the CNS and those involving the PNS. The type and incidence of neurologic complications, the type of immunosuppressive medication used, the type of antirejection treatment used, and the onset of symptoms were evaluated.
The causes of end-stage renal disease in all of the patients and significant medical histories other than chronic renal disease for these patients also were evaluated. used. A total 61 (65.5%) patients, which comprises 7% of the total transplant recipients, presented with some complications involving the peripheral nervous system (PNS). The most common manifestations were tremor in 26.5%, followed by paresthesias in 18.3%, steroid-induced myopathy in 11.8%, ulnar neuropathy in 4.4, and femoral neuropathy in 2.2%. These complications were more common with tacrolimus.
Conclusion:
We conclude that complications involving the neurological system occur in 10 .5% of all transplant patients with 8% involving CNS and 7% involving the PNS. The high mortality rates associated with CNS complications warrant early diagnosis and aggressive treatment in renal transplant recipients.
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3.
Statistical analysis
Descriptive values were presented as mean AE standard deviation. Median values were calculated for variables, which had a wide range. 5% was the level of significance for all univariate and multivariate analyses. Independent t-test was used to compare groups. Comparison between different groups was done by Student's 't'-test for paired and unpaired data and Chisquare test with Yates' correction for ordinal data. SPSS version 15.0 software was used for the above analysis. 
Results

CNS complications
CNS complications were present in 69 (73.3%) patients, which was 8% of total transplant recipients. The common types of CNS complications were infection in 47 (68.1) followed by cerebrovascular accidents in 13 (18.8%), intracranial space occupying lesion in 2 (2.8%), septicemic encephalopathy in 4 (5.8%), hypoglycemic coma in 1 (1.4%), and psychosis in 2 (2.8%) ( Tables 1 and 3) . The most common presentation of CNS complication was headache in 61 (88%), followed by altered sensorium in 49 (71%), fever in 47 (68%), vomiting in 46 (66%), seizure in 38 (55), focal neurological deficits in 20 (29), cranial nerve palsies in 13 (8.8%), and neck rigidity in 29 (42%) ( Table 4 ).
CNS infection
CNS infection was the most common type of CNS complication seen in our study and was present in 47 (68.1%) patients in our study, which comprised 5% of the total renal transplant recipients. Tacrolimus, MMF, and Prednisolone were the most common immunosuppressants used in 18 (38.3%) patients followed by Cyclosporine, MMF, and Prednisolone in 17 (37%); i n d i a n j o u r n a l o f t r a n s p l a n t a t i o n 9 ( 2 0 1 5 ) 1 3 0 -1 3 7
Cyclosporine, azathioprine, and Prednisolone in 6 (13%); Azathioprine and Prednisolone in 5 (10.6); and Cyclosporine and Prednisolone was followed in 1 (2.2%) patient ( (Tables 1, 2, 6 and 7) . The various predisposing factors in patients with CNS infections included antirejection therapy in preceding 3 months in 13 (28.3%), azotemia due to chronic graft dysfunction in 10 (21.7%), preexisting diabetes in 10 (21.7%), nodat in 2 (4.3%), and multiple factors in 8 (17.4%) ( Table 8) .
Fungal infections were the most common type of CNS infection we encountered. The most common being cryptococcal infection in 19 (40.4%). Cryptococcal meningitis accounted for 19 (40.4%) patients with CNS infections. The mean age of the patients was 38.95 AE 11.9 years and they presented after a mean period of 31.3 AE 17.3 (5-60) months after transplantation (Table 5 ). These patients were diagnosed on the basis of CSF examination. CSF examination showed evidence for cryptococcal antigen as well as with positive staining with India ink preparation. MRI scan revealed nonspecific meningial enhancement suggestive of meningitis. Patients in this group were managed with i.v. amphotericin B. Six (31.6%) of the patients did not respond to treatment and died.
One patient (2.1%) had disseminated aspergillosis infection, presented 8 months post-transplantation with fever, i n d i a n j o u r n a l o f t r a n s p l a n t a t i o n 9 ( 2 0 1 5 ) 1 3 0 -1 3 7 headache, and altered sensorium, did not respond to amphotericin B, and died. One patient (2.1%) was found to have aspergillous brain abscess along with pulmonary aspergillosis. Presented with fever, headache, seizures, and right-sided weakness with altered sensorium. He had presented 5 months post-transplant. Diagnosis was made on the basis of CTguided aspiration of brain abscess. MRI head showed multiple lesions with little contrast enhancement. He was given amphotericin B, but did not respond and died (Tables 1 and 2) . One patient (2.1%) was found to have rhinocerebral mucormycosis confirmed on nasal biopsy. He had presented 6 months post-transplant. This patient was diabetic and had received antirejection therapy with i.v. methyl prednisolone 3 months back for acute cellular rejection. This patient too died despite institution of treatment with amphotericin B. Mortality was very high in this group with 9 (41%) deaths out of 22 with fungal infection of CNS. Noncryptococcal fungal infections occurred earlier than cryptococcal infections (8 AE 6.3 vs. 31.3 AE 17.3 months) and was associated with a higher mortality (Tables 1 and 2 ).
Next to fungal infections, bacterial infections were the most common, 14 (29.8%). Tubercular meningitis was most common in this group and was present in 13 (27.7%) patients. Mean age of these patients was 47.6 AE 13.8 years and the mean duration from transplant was 37.31 AE 26.1 months. All of them were treated with ATT with appropriate dose modification. Five patients (38.5%) from this group died (Tables 1 and 2) .
One patient (2.1%) had pyogenic brain abscess, and was diagnosed to have Nocardia asteroids on microscopic examination of the examination of the aspirate. He presented 18 months from the time of transplant. He had responded to treatment with sulfamethoxazole with trimethoprim.
Viral infections were present in 10 (21.3%). Six patients (12.8%) were diagnosed to have viral encephalitis due to Herpes simplex virus. They were all treated with intravenous acyclovir. Mean duration from the time of transplant was 10.83 AE 1.1 months. Mortality was significant with 3 (50%) deaths in this group.
Three patients (6.4%) presented with ipsilateral seventh cranial nerve palsy associated with typical skin lesions of Herpes Zoster. Mean duration from the time of transplant was 12.67 AE 1.5 months. They were managed with i.v. acyclovir and all of them responded.
One patient was found to have cerebral malaria. He had presented with high-grade fever, headache, and followed by altered sensorium. Plasmodium falciparum was detected on examination of blood smear. He responded to treatment with intravenous artesunate.
One patient (2.1%) was detected to have neurocysticercosis on MRI. She had presented with headache, seizures, and lowgrade fever. She was managed with ATT and antiepileptics, and responded to treatment.
Mortality was significant in the patients with posttransplant CNS infections with 17 (36.2%) deaths despite institution of appropriate treatment.
Cerebrovascular accidents
Next to infection, the commonest CNS involvement was cerebrovascular accidents present in 13 (14%) patients; the mean age of the patients was 41.3 AE 9.20 years, and the mean duration from transplant was 31 AE 22.9. Overall stroke was associated with mortality in 3 (23.1%). Eight patients had an ischemic stroke, and responded with persistent residual weakness. Two had intracerebral hemorrhage, presented in very low general condition and both died. Three had subdural hematoma, which was evacuated. Two patients improved with, however one of them died.
Intracranial space occupying lesion
Two patients (2.9%) were found to have intracranial space occupying lesion on MRI. They had presented with headache, vomiting, and seizures with altered sensorium. Possibility of CNS lymphoma was suspected. The mean age of the patients was 43 AE 2 years, and the mean duration from transplant was 21 AE 21.5 months. These two patients had presented with very low general condition and brain biopsy could not be done. Both died despite supportive and antiepileptic treatment before definitive diagnosis could be made.
Others
Four patients had toxic encephalopathy as a result of fulminant systemic sepsis. Mean age was 54 AE 2.3 years and the mean duration was 4.5 AE 1.7 months, from time of transplant. All four had recent history of acute vascular rejection with treatment with ATG as a significant predisposing factor, along with preexisting diabetes. Mortality was very high as all patients in this group had a fatal outcome. One patient had hypoglycemic coma. This patient had posttransplant diabetes mellitus and was on insulin and responded to intravenous dextrose administration with subsequent insulin dose adjustment. Two patients had developed psychosis within seven days of post-transplant period. They developed altered mental status and responded to antipsychotics.
Overall, patients with CNS complications have a high mortality rate, with 26 (37.7%) in our study.
PNS complications
A total of 61 (65.5%) patients, which comprises 7% of the total transplant recipients, presented with complications involving the PNS (Table 4 ). Twenty-five (41%) patients presented with tremors. Majority of them were on tacrolimus-based regimen, 16 (64%) as compared to 8 (32%) on cyclosporine-based regimen ( Table 7) . Paresthesias were present in 17 (27.9%). Majority of them were on tacrolimus, 13 (76) as compared to 4 (23%) on CSA. Nerve conduction studies done suggested axonal pattern in 9 (52%). Eleven patients (18%) presented with i n d i a n j o u r n a l o f t r a n s p l a n t a t i o n 9 ( 2 0 1 5 ) 1 3 0 -1 3 7 steroid-induced myopathy. These patients had significant wasting of proximal group of muscles. EMG studies done in these patients suggested short-duration polyphasic motor unit action potentials. Two patients (3.3%) were diagnosed with Guillain-Barre syndrome. They presented with subacute are flexic quadriparesis, with nerve conduction studies suggestive a proximal demyelinating polyneuropathy. CMV titers were positive in one case and negative in the other. Both were treated with intravenous gancyclovir. One patient started improving in 14 days, and the other in 21 days. Both patients could walk without support with distal weakness persisting in lower limbs after 4 weeks.
Six patients (6.6%) had ulnar neuropathy. They presented with sensory complaints on the medial aspect of the hand, including ring and little fingers. NCV studies in these patients were suggestive of an axonal pattern.
Three (3.3%) had femoral neuropathy. They presented with unilateral weakness of knee extension, loss of patellar reflex, and decreased sensation on anterior-medial aspect of thigh, knee, and calf. Two of them recovered in 6 months, and one patient had incomplete recovery after 12 months.
Discussion
Neurologic complications after renal transplants occur in a significant percentage of patients. In this study, we found neurological complications in 10.8% of the total transplant patients. An early, large retrospective study found neurological complication to be 30% over an 18-year period. 7 Two more recent studies have found lower rates, 8% and 10% over a 26year period and 19-year period, respectively. 5,6 CNS complication in renal transplant patients is an important cause of morbidity and mortality. 9-13 In our study, 8% of all renal transplant recipients followed up at our center developed a CNS complication with an overall mortality of 37.7%. This incidence may be an underestimation because of the retrospective nature of this study and that those developing CNS complications elsewhere and not referred back to this hospital could not be included. The incidence of CNS complications depends on the type of organ transplanted, type and intensity of immunosuppression used, and the geographical region from where it is reported, as infective complications are likely to be seen more frequently in the tropics especially in populations with a less advantageous socio-economic background.
Moreover, the incidence could vary according to the nature of the study, i.e. retrospective vs. prospective and clinical vs. autopsy series. The incidence of CNS infections was higher in autopsies of renal transplant recipients, i.e. 47% reported by Morton et al. 13 from UK as compared to 4% in an American clinical cum autopsy series. 14 Cerebrovascular events in the latter study occurred in 9.5% patients and accounted for 25% of all deaths. In a clinical and autopsy series reported from south India, CNS complications were seen in 6.9% of 550 renal transplants patients over a 15-year period (12) . CNS infections were diagnosed in 2.9% of all transplant recipients and accounted for the largest group (42.1%) followed by cerebrovascular accidents in 23.7%. The overall mortality rate was 60.5% in patients with CNS complications in the study. 12 Unfortunately, prospective clinical data on CNS complications in renal transplant recipients are not forth coming.
There are no series on CNS complications following nonrenal organ transplants from the Asian continent, although these have been reported from other parts of the world. Neurologic complications occur in 60-70% of allogenic bone marrow transplant patients, and are the cause of death in 5-10%. 15 Cerebrovascular accidents were seen in 26.6% of autopsied patients in an American series, whilst CNS infections occurred in 12.8%. 16 After heart transplant, approximately 60% patients develop neurological complications predominantly due to cerebrovascular accidents. In liver transplant recipients, clinical studies have documented CNS complications in 20-30% patients in contrast autopsy series where 72% of patients had a pathology involving nervous system with cerebrovascular lesions in the majority. 15, 17 Several factors that predispose toward development of CNS complications in renal transplant recipients include impaired host defenses, glucose intolerance, leucopenia mostly as a result of azathiprine or cytomegalovirus infection, hypertension, or hyperlipidemia. 10 In our series, multiple predisposing factors, such as antirejection therapy in the preceding 3 months, preexisting diabetes mellitus, NODAT, and chronic allograft dysfunction associated azotemia were present in almost 93% of patients who presented with CNS infections post-transplant. 19 CNS infections are the largest group among all CNS complications in renal transplant patients in our study, and found in 68.1%, as reported from other series. 5, 11, 12 Almost 63% of fungal infection in post-transplant patients affects the CNS. 20 The etiopathogenic spectrum of CNS infections varies in different series. In our study, we found that the organisms causing CNS infections in a tropical country like India varies from that reported from the west. In the present series, Cryptococcus neoformans alone was responsible for more than one-third of all CNS infections, whereas CNS aspergillosis was seen in two and mucormycosis in one patient. Similar incidence has been observed in other studies from India. 5 We did not see any cases of candida or listeria that have been reported from other series. 15, 21 The second commonest type of CNS infection in our series is tubercular meningitis in 27.7% of patients with CNS complications. This was 1.5% of total renal transplant recipients. Tuberculosis is the commonest organism on bronchoalveolar lavage in renal transplant recipients documented in nearly 13%. 23 The reason for such low incidence of tuberculosis in CNS is not known. One possible reason could be the high index of suspicion for tuberculosis we have had for years, with many patients with pyrexia of unknown origin having been treated with antitubercular therapy empirically at this center before the infection actually disseminates or becomes manifest in organs, such as the CNS. 22, 23 We encountered two cases of aspergillosis and one case of rhinocerebral mucormycosis. All three had a fatal outcome as reported for such infections in other series. 5, 24 CNS infections in renal transplant recipients carry a high mortality in the present series; 36.2% of patients with CNS infection died as a result of these infections. This is in keeping with mortality rates of 35-71% that have been reported. 11, 15, 21 We could not find any association between the use of cyclosporine immunosuppression and the type of CNS infection or the time of onset of the infection.
Next to infection, the commonest CNS involvement was cerebrovascular accidents present in 13 (14%) patients in this series. Several risk factors in renal transplant patients predispose for cerebrovascular underlying renal disease, such as intracranial aneurysm in autosomal dominant polycystic kidney disease.
Four patients had toxic encephalopathy as a result of fulminant systemic sepsis. All four had recent history of acute vascular rejection with treatment with ATG as a significant predisposing factor, along with preexisting diabetes. Mortality was very high as all patients in this group had a fatal outcome. Encephalopathy and coma account for 26% of patients after bone marrow transplantation and are commonly associated with terminal events. 25 Overall, patients with CNS complications have a high mortality rate with 26 (37.7%) in our study as reported from other studies.
Amongst the complications involving the PNS in our series, the most common was tremors (41%). Majority of them were on tacrolimus 64% as compared to 32% on cyclosporine-based regimen. Paresthesias were present in 27.9% in our study. Majority of them were on tacrolimus, 76% as compared to 23% on cyclosporine. In a prospective randomized trial of 400 patients after renal transplantation, tacrolimus group reported higher rates of all neurological side effects; tremor was significantly greater in the tacrolimus than the cyclosporine group (54% vs. 34%) as were paresthesias (23% vs. 15%). 30 Eleven patients (18%) presented with steroid-induced myopathy. These patients had significant wasting of proximal group of muscles. Steroid-induced myopathy in renal transplant patients does not seem to be dose dependent, occurring with both acute and long-term uses. 31 Two patients (3.3%) presented with Guillain-Barre syndrome. CMV titers were positive in one case and negative in the other; both were treated with intravenous gancyclovir. One patient started improving in 14 days, the other in 21 days. Both patients could walk with out support with distal weakness persisting in lower limbs. The occurrence of Guillain-Barre syndrome in postrenal transplant and its association with cytomegalovirus has been reported in earlier studies. 32 Six patients (6.6%) had ulnar neuropathy and three (3.3%) had femoral neuropathy, occurrence of both of which has been in reported in a small percentage of postrenal transplant patients. [33] [34] [35] [36] 
Conclusion
Neurological complications occur in 10.8% of all renal transplant recipients. CNS complications in 8% of all with infections being the largest group. Pathogens producing CNS infections in our country differ from those reported from elsewhere. Fungal infections of the CNS are the commonest etiological agents. Patient with noncryptococcal infection and septicemic encephalopathy had the worst outcomes.
The common peripheral nervous complications were tremors and paresthesias, and were more common with tacrolimus as compared to cyclosporine. The high mortality rates associated with CNS complications warrant early diagnosis and aggressive treatment in renal transplant recipients.
